Breast cancer is one of the most common cancers in women and contributes to more than a quarter of new cancer cases each year. Screening and other preventive measures are available, but often recommended only to women who have a family history of the disease, and when screening is carried out, it is often for only a limited set of high-risk genes such as BRCA1 and BRCA2. ABCA4 encodes ATP-binding cassette subfamily A member 4. Its protein product removes toxic substances following phototransduction from retinal photoreceptors. ABCA4-associated disease encompasses an array of autosomal recessive inherited retinal diseases. Stargardt disease is one of the most prevalent retinopathies, but biallelic ABCA4 variants are also linked to cone-rod dystrophy, atypical retinitis pigmentosa, and fundus flavimaculatus among other retinal dystrophies. More than 800 variants characterize ABCA4-associated disease, most of which are located in the coding region. Yet these variants explain only 60% to 75% of cases, which suggests missing heritability in noncoding regions. In this issue Bauwens et al. unravel missing heritability in a small cohort of European ABCA4-associated disease patients with one heterozygous or no identified pathogenic variant. The researchers enriched a conserved region surrounding the ABCA4 gene before performing next-generation sequencing of patient samples. They first analyzed variants within the coding region and identified known pathogenic variants. Then they assessed any remaining variants in noncoding regions for predicted effects on splice sites, exonic splice enhancers, and splice silencers. They also investigated rare variants outside of regulatory regions. All together, the analysis resulted in a molecular diagnosis in 84% (56/67) of patients. The hypomorphic variant c.5603A > T was the most common missing allele, occurring in 43% of cases (29/67). Noncoding splice variants and copy-number variations also contributed substantially, making up 31% (21/67) and 9% (6/67) of cases, respectively. The analysis revealed eight pathogenic (deep-) intronic ABCA4 splice variants, including five novel ones, as well as six structural variants, four of which are novel and include two duplications. Aside from providing new knowledge likely to improve diagnostics, the findings led the investigators to identify potential treatment implications. Antisense oligonucleotide treatment in HEK293-T cells and patient-derived fibroblasts rescued aberrant splicing for three variants (c.859-540C > G, c.4539+1106C > T, and c.5197-557G > T). The results indicate that treatment could restore messenger RNA (mRNA) levels and subsequently ABCA4 protein to normal in vivo, the researchers report. They acknowledge that the analysis cannot exclude pathogenic variants in other genes, but propose that their approach could be used as a model to identify missing heritability in other autosomal recessive diseases. -V. L. Dengler, News Editor
